Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.74 |
| ▸ | MEN1 | O00255 | 4/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.74 |
| ▸ | GLA | P06280 | 2/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | HTT | P42858 | 1/20 | 0.74 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
| ▸ | KDM1A | O60341 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.60 |
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17154448 | 0.94 | KMT2A (0.62) | KMT2AMEN1KDM4EGLAMAPT | |
| SCHEMBL17154366 | 0.91 | KMT2A (0.60) | KMT2AMEN1KDM4EGLAMAPT | |
| SCHEMBL12018981 | 0.86 | KMT2A (1.00) | KMT2AMEN1KDM4EGLAMAPT | |
| SCHEMBL17154442 | 0.85 | KMT2A (0.53) | KMT2AMEN1KDM4EGLAMAPT | |
| SCHEMBL17154393 | 0.83 | KMT2A (0.66) | KMT2AMEN1KDM4EGLAMAPT | |
| SCHEMBL17154372 | 0.83 | KMT2A (0.50) | KMT2AMEN1KDM4EGLAMAPT | |
| SCHEMBL17154459 | 0.83 | KMT2A (0.50) | KMT2AMEN1KDM4EGLAMAPT | |
| SCHEMBL17154394 | 0.83 | KDM1A (0.84) | KMT2AMEN1KDM4EGLAMAPT | |
| SCHEMBL17154412 | 0.82 | KMT2A (0.57) | KMT2AMEN1KDM4EGLAMAPT | |
| SCHEMBL17154450 | 0.81 | KDM1A (1.00) | KMT2AMEN1KDM4EGLAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170022166-A1 | NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT | MIRX PHARMACEUTICALS LLC (US) | 2017-01-26 | — | — | US | disclosed |
| US-20170022166-A1 | NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT | MIRX PHARMACEUTICALS LLC (US) | 2017-01-26 | — | — | US | disclosed |
| WO-2015153535-A1 | NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT | MiRx Pharmaceuticals, LLC (US) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022166-A1 | NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT | TP53, DDX3X, API5 | KMT2A 1544/4885MEN1 2446/4885KDM4E 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.